These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 21757141

  • 1. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up.
    Liao YN, Liu CS, Tsai TR, Hung YC, Chang SJ, Lin HL, Chen YC, Lai HM, Yu SF, Chen CJ.
    Kaohsiung J Med Sci; 2011 Jul; 27(7):251-7. PubMed ID: 21757141
    [Abstract] [Full Text] [Related]

  • 2. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB.
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [Abstract] [Full Text] [Related]

  • 3. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus.
    Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S.
    Arthritis Rheum; 2010 Aug; 62(8):2467-75. PubMed ID: 20506343
    [Abstract] [Full Text] [Related]

  • 4. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
    Oelzner P, Deliyska B, Fünfstück R, Hein G, Herrmann D, Stein G.
    Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
    [Abstract] [Full Text] [Related]

  • 5. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.
    Carneiro JR, Sato EI.
    J Rheumatol; 1999 Jun; 26(6):1275-9. PubMed ID: 10381042
    [Abstract] [Full Text] [Related]

  • 6. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus.
    Miyawaki S, Nishiyama S, Aita T, Yoshinaga Y.
    Mod Rheumatol; 2013 Jul; 23(4):659-66. PubMed ID: 23011357
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The contribution of resting heart rate and routine blood tests to the clinical assessment of disease activity in systemic lupus erythematosus.
    Guzmán J, Cardiel MH, Arce-Salinas A, Alarcón-Segovia D.
    J Rheumatol; 1994 Oct; 21(10):1845-8. PubMed ID: 7837148
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS.
    Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
    [Abstract] [Full Text] [Related]

  • 12. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA.
    Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
    [Abstract] [Full Text] [Related]

  • 13. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
    Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, Andrassy K.
    Scand J Rheumatol; 2007 Dec; 36(4):291-8. PubMed ID: 17763207
    [Abstract] [Full Text] [Related]

  • 14. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
    Hepburn AL, Mason JC, Davies KA.
    Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618
    [Abstract] [Full Text] [Related]

  • 15. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
    Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, LJP 394-90-09 Investigator Consortium.
    Arthritis Rheum; 2008 Aug; 58(8):2470-80. PubMed ID: 18668592
    [Abstract] [Full Text] [Related]

  • 16. Prolonged remission in systemic lupus erythematosus.
    Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD.
    J Rheumatol; 2005 Aug; 32(8):1467-72. PubMed ID: 16078321
    [Abstract] [Full Text] [Related]

  • 17. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
    Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA, PEARL-SC Study.
    Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
    [Abstract] [Full Text] [Related]

  • 18. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
    Ezeonyeji AN, Isenberg DA.
    Rheumatology (Oxford); 2012 Mar; 51(3):476-81. PubMed ID: 22096015
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus].
    Francioni C, Fioravanti A, Gelli R, Megale F, Marcolongo R.
    Recenti Prog Med; 1993 Oct; 84(10):679-86. PubMed ID: 8235034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.